Format

Send to:

Choose Destination
See comment in PubMed Commons below
Discov Med. 2013 Jan;15(80):43-9.

Genetics and genetic testing of dilated cardiomyopathy: a new perspective.

Author information

  • 1Cardiovascular Institute, University of Colorado, Aurora, CO 80305, USA. luisa.mestroni@ucdenver.edu

Abstract

The completion of the Human Genome Project was a landmark achievement, but as clinical genetic testing becomes more mainstream, the extent of remarkable genetic variation is increasingly being appreciated. Newer DNA sequencing technology can now complete the sequencing of an entire human genome several times over in a matter of days, but this will undoubtedly add new challenges to the difficulty of distinguishing true pathogenic variants from benign variants in diagnostic genetics and in the research setting. The recent discovery of the role of titin gene (TTN) mutations in dilated cardiomyopathy (DCM) will make genetic testing in this disease more efficient. Furthermore, better understanding of genotype-phenotype associations will assist clinicians in identifying early stages of disease and providing more appropriate treatments. This high level of complexity requires an expert genetic team to offer counseling and to manage, deliver, and follow-up over time the results of genetic testing, which is particularly important for screening of family members potentially at risk. In DCM, genetic testing may be useful for the identification of non-carriers and asymptomatic carriers, as well as for prevention strategies, sport recommendations, and defibrillator implantation. It can also guide reproductive decision-making including utilization of pre-implantation genetic diagnostic strategies.

PMID:
23375013
[PubMed - indexed for MEDLINE]
PMCID:
PMC3929942
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Discovery Medicine Icon for PubMed Central
    Loading ...
    Write to the Help Desk